TSE:AUP - Isotechnika Pharma Stock Price, Price Target & More

Get Started

C$7.80 +0.01 (+0.13 %)

(As of 05/21/2018 12:39 PM ET)

Previous CloseC$7.79

Today's RangeC$7.76 - C$8.03

52-Week RangeC$5.68 - C$9.82

Volume16,244 shs

Average Volume46,376 shs

Market CapitalizationC$596.22 million

P/E RatioN/A

Dividend YieldN/A

Beta3.34

About Isotechnika Pharma (TSE:AUP)

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.

Receive AUP News and Ratings via Email

Sign-up to receive the latest news and ratings for AUP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Technical & System Software

Sub-IndustryN/A

SectorComputer and Technology

SymbolTSE:AUP

CUSIPN/A

Webwww.auriniapharma.com

Phone+1-250-7084272

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net Margins-45,241.38%

Return on Equity-30.41%

Return on Assets-25.82%

Miscellaneous

EmployeesN/A

Outstanding Shares84,052,000

Isotechnika Pharma (TSE:AUP) Frequently Asked Questions

What is Isotechnika Pharma's stock symbol?

Isotechnika Pharma trades on the Toronto Stock Exchange (TSX) under the ticker symbol "AUP."

How were Isotechnika Pharma's earnings last quarter?

Isotechnika Pharma Inc. (TSE:AUP) released its quarterly earnings results on Thursday, May, 10th. The company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.21) by $0.02. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.07 million. Isotechnika Pharma had a negative return on equity of 30.41% and a negative net margin of 45,241.38%. View Isotechnika Pharma's Earnings History.

When is Isotechnika Pharma's next earnings date?

Isotechnika Pharma is scheduled to release their next quarterly earnings announcement on Thursday, August, 9th 2018. View Earnings Estimates for Isotechnika Pharma.

Who are some of Isotechnika Pharma's key competitors?

Some companies that are related to Isotechnika Pharma include IRESS (IRE), Computer Modelling Group (CMG), GB Group (GBG), Emis Group (EMIS), WANdisco (WAND), SDL (SDL), Microgen (MCGN), Absolute Software (ABT), dotmailer (DOTD), Tecsys (TCS), Datum International (IDEA), Isentia (ISD), Smart Parking (SPZ), Idox (IDOX) and Gresham Technologies (GHT).

Who are Isotechnika Pharma's key executives?

Isotechnika Pharma's management team includes the folowing people:

Dr. Richard M. Glickman, Founder, Chairman & CEO (Age 60)
Mr. Michael R. Martin, Co-Founder and Chief Operating Officer
Mr. Dennis Bourgeault, CFO & Sec.
Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.
Dr. Neil Solomons M.D., Chief Medical Officer

Has Isotechnika Pharma been receiving favorable news coverage?

Press coverage about AUP stock has trended very positive on Monday, Accern reports. The research group identifies positive and negative media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Isotechnika Pharma earned a media sentiment score of 0.51 on Accern's scale. They also assigned news articles about the company an impact score of 47.26 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Isotechnika Pharma?

Shares of AUP and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Isotechnika Pharma's stock price today?

One share of AUP stock can currently be purchased for approximately C$7.80.

How big of a company is Isotechnika Pharma?

Isotechnika Pharma has a market capitalization of C$596.22 million.

How can I contact Isotechnika Pharma?

Isotechnika Pharma's mailing address is 1203-4464 Markham St, VICTORIA, BC V8Z 7X8, Canada. The company can be reached via phone at +1-250-7084272.

MarketBeat Community Rating for Isotechnika Pharma (AUP)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		92 (Vote Outperform)
Underperform Votes:		74 (Vote Underperform)
Total Votes:		166

MarketBeat's community ratings are surveys of what our community members think about Isotechnika Pharma and other stocks. Vote "Outperform" if you believe AUP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AUP will underperform the S&P 500 over the long term. You may vote once every thirty days.

Isotechnika Pharma (TSE:AUP) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Isotechnika Pharma in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Isotechnika Pharma (TSE:AUP) Consensus Price Target History

Price Target History for Isotechnika Pharma (TSE:AUP)

Isotechnika Pharma (TSE:AUP) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating
10/6/2017	Seaport Global Securities	Reiterated Rating	Buy
5/15/2017	Leerink Swann	Reiterated Rating	Outperform
11/4/2016	Bloom Burton	Reiterated Rating	Buy
11/1/2016	Mackie	Reiterated Rating	Speculative Buy

(Data available from 5/21/2016 forward)

Isotechnika Pharma (TSE:AUP) Earnings History and Estimates Chart

Earnings by Quarter for Isotechnika Pharma (TSE:AUP)

Isotechnika Pharma (TSE:AUP) Earnings Estimates

2018 EPS Consensus Estimate: ($0.96)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.25)	($0.25)	($0.25)
Q2 2018	1	($0.23)	($0.23)	($0.23)
Q3 2018	1	($0.23)	($0.23)	($0.23)
Q4 2018	1	($0.25)	($0.25)	($0.25)

Isotechnika Pharma (TSE AUP) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
8/9/2018
5/10/2018	Q1 2018	C($0.21)	C($0.23)	C$0.07 million	C$0.04 million	View	N/A
3/15/2018	Q4 2017	C($0.18)	C($0.05)	C$0.07 million	C$0.04 million	View	N/A
11/14/2017	Q3 2017	C($0.18)	C($0.20)	C$0.17 million	C$0.04 million	View	N/A
8/10/2017	Q2 2017	C($0.17)	C($0.04)	C$0.08 million	C$0.44 million	View	N/A
5/15/2017	Q1 2017		C($0.27)		C$0.04 million	View	N/A
3/9/2017	Q4 2016		C($0.29)		C$0.04 million	View	N/A
11/4/2016	Q3 2016		C($0.25)		C$0.04 million	View	N/A
8/5/2016	Q2 2016		C($0.18)		C$0.07 million	View	N/A
5/11/2016	Q1 2016		C($0.18)		C$0.08 million	View	N/A
3/18/2016	Q4 2015		C($0.21)		C$0.08 million	View	N/A
11/13/2015	Q3 2015		C($0.24)		C$0.08 million	View	N/A
8/11/2015	Q2 2015		C($0.03)		C$0.07 million	View	N/A
5/15/2015	Q1 2015		C($0.32)		C$0.07 million	View	N/A
3/30/2015	Q4 2014		C($0.19)		C$0.09 million	View	N/A
11/12/2014	Q3 2014		C($0.09)		C$0.08 million	View	N/A
8/14/2014	Q2 2014		C($0.14)		C$0.08 million	View	N/A
5/15/2014	Q1 2014		C($0.26)		C$0.07 million	View	N/A
3/31/2014	Q4 2013		C$0.12		C$0.75 million	View	N/A
11/21/2013	Q3 2013		C($0.01)		C$0.09 million	View	N/A
8/13/2013	Q2 2013		C($0.50)		C$0.09 million	View	N/A
4/3/2013	Q4 2012		C($2.00)			View	N/A
11/13/2012	Q3 2012		C($0.50)			View	N/A
8/14/2012	Q2 2012		C($0.50)			View	N/A
5/11/2012	Q1 2012		C($0.15)			View	N/A
3/13/2012	Q4 2011		C($0.60)			View	N/A
11/10/2011	Q3 2011		C$0.65			View	N/A
8/6/2011	Q1 2011		C($0.65)			View	N/A
7/29/2011	Q2 2011		C$0.10			View	N/A
3/25/2011	Q4 2010		C($1.00)			View	N/A
11/9/2010	Q3 2010		C($0.50)			View	N/A
8/11/2010	Q2 2010		C($0.20)			View	N/A
5/12/2010	Q1 2010		C($0.60)			View	N/A
3/24/2010	Q4 2009		C($0.50)			View	N/A
11/11/2009	Q3 2009		C($0.50)			View	N/A
8/6/2009	Q2 2009		C($0.90)			View	N/A
5/14/2009	Q1 2009		C($1.95)			View	N/A
3/27/2009	Q4 2008		C($2.50)			View	N/A
8/6/2008	Q2 2008		C($2.50)			View	N/A
5/6/2008	Q1 2008		C($2.50)			View	N/A
3/19/2008	Q4 2007		C($4.00)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Isotechnika Pharma (TSE:AUP) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Isotechnika Pharma (TSE AUP) Insider Trading and Institutional Ownership History

Insider Trading History for Isotechnika Pharma (TSE:AUP)

Isotechnika Pharma (TSE AUP) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/12/2017	Rashieda Gluck	Insider	Buy	50	C$0.10	C$5.00
3/23/2016	Rashieda Gluck	Insider	Sell	1,500	C$3.00	C$4,500.00

(Data available from 1/1/2013 forward)

Isotechnika Pharma (TSE AUP) News Headlines

Source:

Date	Headline
	Equities Analysts Offer Predictions for Isotechnika Pharma Inc.'s FY2018 Earnings (AUP) www.americanbankingnews.com - May 17 at 8:16 AM
	Edited Transcript of AUP.TO earnings conference call or presentation 10-May-18 8:30pm GMT finance.yahoo.com - May 11 at 10:38 AM
	Aurinia Reports First Quarter Financial Results and Operational Highlights finance.yahoo.com - May 10 at 4:27 PM
	Isotechnika Pharma (AUP) Scheduled to Post Earnings on Thursday www.americanbankingnews.com - May 3 at 3:19 AM
	Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018 finance.yahoo.com - April 25 at 4:30 PM
	Aurinia Pharmaceuticals (AUP) Given Buy Rating at Seaport Global Securities www.americanbankingnews.com - April 7 at 6:36 PM
	Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 finance.yahoo.com - April 2 at 4:22 PM
	FY2018 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Analyst (AUP) www.americanbankingnews.com - March 23 at 9:56 AM
	Aurinia Pharmaceuticals Inc Forecasted to Earn Q1 2018 Earnings of ($0.25) Per Share (AUP) www.americanbankingnews.com - March 19 at 1:04 AM
	Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights - Business Wire (press release) www.businesswire.com - March 17 at 4:54 PM
	Edited Transcript of AUP.TO earnings conference call or presentation 15-Mar-18 8:30pm GMT finance.yahoo.com - March 16 at 5:14 PM
	Today’s Research Reports on Aurinia Pharmaceuticals, Revive Therapeutics, Canopy Growth and Spectral Medical finance.yahoo.com - March 15 at 9:34 AM
	Aurinia Pharmaceuticals (AUP) to Release Earnings on Thursday www.americanbankingnews.com - March 8 at 1:30 AM
	Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors finance.yahoo.com - February 22 at 4:43 PM
	Today’s Research Reports on Aurinia Pharmaceuticals, Crescita Therapeutics, CanniMed Therapeutics and Titan Medical finance.yahoo.com - February 20 at 9:13 AM
	Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program finance.yahoo.com - February 14 at 9:03 AM
	Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference finance.yahoo.com - February 6 at 9:01 AM
	Toronto Exchanges Stock Review, Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International finance.yahoo.com - January 16 at 9:03 AM
	Edited Transcript of AUP.TO earnings conference call or presentation 14-Nov-17 9:30pm GMT finance.yahoo.com - January 15 at 5:48 PM
	Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus finance.yahoo.com - January 4 at 5:50 PM
	Aurinia Pharmaceuticals Inc (AUPH) Shares Dip on New Shelf Registration finance.yahoo.com - January 4 at 5:50 PM
	Is Aurinia Pharmaceuticals a Buy? finance.yahoo.com - December 19 at 8:57 AM
	Canadian Exchanges Stock Scanner Oncolytics Biotech, Aurinia Pharmaceuticals, Immunovaccine, and IntelliPharmaCeutics International finance.yahoo.com - December 14 at 9:01 AM
	Aurinia Pharmaceuticals Inc (AUPH) to Enter NASDAQ Biotech Index finance.yahoo.com - December 12 at 9:23 AM
	Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index finance.yahoo.com - December 11 at 4:16 PM
	Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q3, 2017 By the Numbers : November 23, 2017 finance.yahoo.com - November 23 at 3:38 PM
	FY2017 EPS Estimates for Aurinia Pharmaceuticals Inc Cut by Cantor Fitzgerald (AUP) www.americanbankingnews.com - November 22 at 5:54 AM
	Brokers Issue Forecasts for Aurinia Pharmaceuticals Inc's Q4 2017 Earnings (AUP) www.americanbankingnews.com - November 17 at 10:12 PM
	FY2017 Earnings Estimate for Aurinia Pharmaceuticals Inc (AUP) Issued By Leerink Swann www.americanbankingnews.com - November 17 at 8:08 PM
	14 Stocks Moving In Tuesday's After-Hours Session - Benzinga www.benzinga.com - November 15 at 2:43 AM
	Aurinia Reports Third Quarter 2017 Financial Results and Provides Operational Highlights - Business Wire (press release) www.businesswire.com - November 15 at 2:43 AM
	Aurinia Pharmaceuticals Inc (AUP) Set to Announce Quarterly Earnings on Tuesday www.americanbankingnews.com - November 8 at 10:14 AM
	Cramer's lightning round: I'm concerned about GameStop ahead of the holidays - CNBC www.cnbc.com - November 4 at 5:46 PM
	Aurinia Pharmaceuticals: R&D Day Update On Its Clinical Program And Pipeline Development seekingalpha.com - October 31 at 3:12 AM
	Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : October 23, 2017 finance.yahoo.com - October 23 at 3:57 PM
	Aurinia to Expand Renal Franchise with Novel Indications and Launches Development Program for Treatment of Dry ... - Business Wire (press release) www.businesswire.com - October 21 at 8:58 PM
	Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap - Motley Fool www.fool.com - October 15 at 2:06 AM
	Should You Buy Aurinia Pharmaceuticals Inc (AUPH)? finance.yahoo.com - October 13 at 9:50 PM
	Why High-Flying Aurinia Pharmaceuticals Stock Could Still Be Dirt Cheap finance.yahoo.com - October 13 at 4:50 PM
	Millennial investor mindful of Indigenous rights and climate change - The Globe and Mail www.theglobeandmail.com - October 7 at 4:51 PM
	Research Initiated on Healthcare Stocks, Oncolytics Biotech, Aurinia Pharma, Immunovaccine, and IntelliPharmaCeutics International finance.yahoo.com - October 3 at 3:57 PM
	Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 29, 2017 finance.yahoo.com - October 2 at 4:07 PM
	Aurinia Pharmaceuticals, Inc. – Value Analysis (TORONTO:AUP) : October 2, 2017 finance.yahoo.com - October 2 at 4:07 PM
	Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AUP-CA : September 13, 2017 finance.yahoo.com - September 13 at 5:25 PM
	Aurinia Pharmaceuticals stock has tripled so far in 2017. Here's why that could be just the start. - Motley Fool www.fool.com - September 2 at 8:54 PM
	Aurinia Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : AUP-CA : September 1, 2017 finance.yahoo.com - September 1 at 4:45 PM
	Too Many People Own Stocks finance.yahoo.com - August 31 at 9:10 PM
	Aurinia Pharmaceuticals Inc Expected to Earn FY2017 Earnings of ($1.27) Per Share (AUP) www.americanbankingnews.com - August 28 at 2:28 AM
	3 Reasons to Buy Aurinia Pharmaceuticals Stock Right Now finance.yahoo.com - August 25 at 2:20 AM
	Aurinia Pharmaceuticals, Inc. :AUP-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 15, 2017 finance.yahoo.com - August 15 at 5:08 PM

Isotechnika Pharma (TSE:AUP) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Financials are not available for this stock.

Isotechnika Pharma (TSE AUP) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff